




20<sup>TH</sup> INTERNATIONAL SYMPOSIUM ON  
**THROMBOEMBOLISM**

18-19 OCTOBER 2013, THE QUEEN ELIZABETH II CONFERENCE CENTRE, LONDON, UK



**Delegate Book**

**Front cover image:**

*The Houses of Parliament, Sunset* painted by Claude Monet in 1903.

Dear Colleagues,

It is my great pleasure to welcome you to London to participate in the 20th International Symposium on Thromboembolism organized under the auspices of the Thrombosis Research Institute. Once again we are privileged to be able to bring together globally acknowledged leaders and experts from the rapidly developing field of thromboembolism and anticoagulation to help colleagues from around the world focus on how best to translate the latest research into responsible clinical practice.

Features of the 20th IST include a broad range of in-depth plenary sessions covering thromboembolic stroke, arterial thrombosis, cancer-associated thrombosis and venous thromboembolism, combined with interactive 'meet the expert' sessions, workshops and a debate. These smaller sessions with our international faculty provide a unique opportunity to explore how best innovation in anticoagulation might best be applied to improve clinical outcomes for our patients.

We are delighted to be in London for what promises to be a most informative and rewarding symposium.

With best wishes,



Professor the Lord Kakkar  
Chair



Providing excellence in research, education, and patient care, and internationally renowned for pioneering, multidisciplinary research, the Thrombosis Research Institute comprises 2 independent charitable foundations based in London, United Kingdom, and Bangalore, India. The Thrombosis Research Institutes are dedicated to the study of thrombosis and related disorders.

The 2 research establishments are united by their shared mission: To provide excellence in thrombosis research, education, and patient care, and to develop new strategies to prevent and treat thrombosis, thereby reducing health care costs and saving millions of lives.

The Thrombosis Research Institute, London, was established in 1989, with the backing of then Prime Minister, Margaret Thatcher. It was created specifically to conduct research in cardiovascular disease (of the heart and blood vessels), a major cause of death and disability throughout the world.

This was followed in 2006 with the founding of the Thrombosis Research Institute in Bangalore, which was officially opened and dedicated to the nation by then president of India, His Excellency Dr A P J Abdul Kalam. This second facility was set up to study the genetics of heart disease, particularly among the South Asian population, many of whom seem to have specific predisposing genetic characteristics, and to develop novel and affordable therapies for disease prevention and treatment.

The 2 institutions, whose combined research activities encompass drug discovery and basic scientific, clinical, and epidemiological studies, are primarily concerned with understanding the disease process, developing novel and affordable therapies, and identifying those most at risk at an early age.

In addition, the London Institute is heavily involved in promoting the adoption of evidence-based methods of prevention and treatment to ensure that knowledge from groundbreaking research quickly informs routine clinical practice and benefits patients as soon as possible.

For more information, please visit the Thrombosis Research Institute's website at **[www.tri-london.ac.uk](http://www.tri-london.ac.uk)**.

## Programme Overview

The 20th International Symposium on Thromboembolism (IST) will focus on the advances and changes in the field of thromboembolism, while maintaining its commitment to the presentation of evidence-based medicine and helping clinicians translate research into clinical practice. The combination of the various formats at the IST allows attendees to be exposed to new data and allows for the interactivity with colleagues from around the world.

## Target Audience

Cardiologists, oncologists, surgeons, haematologists, general practitioners, internal medicine specialists, pharmacists, nurses, and other healthcare professionals involved in the care of patients at risk or with thromboembolic disease.

## Learning Objectives

Upon completion of this activity, participants should be able to:

- Provide a comprehensive overview of the state of the art in the treatment of cancer associated, venous and arterial thromboembolic disease, to broaden the delegates knowledge.
- Evaluate current understanding of cancer associated, venous and arterial thromboembolic disease to increase delegate's awareness of the subject.
- Encourage dissemination of this new information and best practice to delegates through the varied plenary sessions and interactive workshops and meet the expert opportunities.

## Accreditation

This activity has been planned and implemented by Thrombosis Education Ltd. In accordance with all requirements from the Royal College of Physicians (RCP).

The 20th International Symposium on Thromboembolism has been approved by the Federation of the Royal Colleges of Physicians of the United Kingdom for 9 category 1 (external) CPD credit(s).

## Sponsorship

This event is supported by



**Bayer HealthCare**  
Pharmaceuticals



**Boehringer  
Ingelheim**



**Daiichi-Sankyo**



**SANOFI**



## Level 4



## Level 5



## Level 6











**Day One Friday 18 October 2013**

**13.00 – 14.30 Registration**

**14.30 – 14.45 Welcome Remarks** *Mountbatten Room*  
*Lord Kakkar, UK (Chair)*

**14.45 – 16.15 20 Years of IST: A Window on Thrombosis Innovation**  
*Chairs: S Goldhaber, USA and W Kakkar, UK*

1. Venous thromboembolism  
*M Levine, Canada*
2. Coronary artery disease  
*JP Bassand, France*
3. Thromboembolic stroke  
*D Atar, Norway*

**16.15 – 17.45 Plenary Session I: Thromboembolic Stroke**  
*Chairs: JP Bassand and AGG Turpie, Canada*

1. Stroke – The coming epidemic  
*W Hacke, Germany*
2. Assessing stroke and bleeding risk:  
How can we do better?  
*S Goto, Japan*
3. The challenge and opportunities for stroke prevention in AF  
*AJ Camm, UK*

**Day Two Saturday 19 October 2013**

**08.30 – 09.30 Meet the Expert Sessions**

- I. Optimising CV risk in hospitalized patients *Rutherford*  
*J Mega, USA*
- II. NOACs and contemporary cardiology practice *Henry Moore*  
*KAA Fox, UK*
- III. Thrombophilia screening *Abbey*  
*R Bauersachs, Germany*
- IV. Post-thrombotic syndrome *Wesley*  
*P Prandoni, Italy*

**09.30 – 11.00 Plenary Session II: Arterial Thrombosis** *Mountbatten Room*  
*Chair: JP Bassand and AJ Camm*

1. Pathogenesis of atherosclerosis  
– Where might therapy be going  
*KAA Fox*
2. Predicting risk for recurrent coronary events  
*W Kakkar*
3. How should we manage residual risk of ACS?  
*J Mega*

**11.00 – 11.30 Tea** *Mountbatten Lounge*

<b>11.30 – 12.30</b>	<b>Workshops</b>	
	<b>1. Cancer</b>	<i>Rutherford</i>
	<i>Chairs: M Levine and MM Samama, France</i>	
	<ul style="list-style-type: none"><li>• Predicting risk for VTE in cancer <i>A Falanga, Italy</i></li><li>• Duration of secondary VTE prevention <i>C Kessler, USA</i></li></ul>	
	<b>2. Medical Patients</b>	<i>Abbey</i>
	<i>Chairs: S Haas, Germany and VV Kakkar</i>	
	<ul style="list-style-type: none"><li>• Prophylaxis short or extended <i>R Bauersachs</i></li><li>• Biomarkers to predict risk <i>S Goldhaber</i></li></ul>	
	<b>3. Atrial Fibrillation</b>	<i>Henry Moore</i>
	<i>Chairs: Lord Kakkar and AGG Turpie</i>	
	<ul style="list-style-type: none"><li>• Secondary prevention of stroke <i>D Atar</i></li><li>• What the registries are telling us <i>S Goto</i></li></ul>	
<b>12.30 – 13.45</b>	<b>Lunch</b>	<i>Mountbatten Lounge</i>
<b>13.45 – 15.15</b>	<b>Plenary Session III: Cancer-associated Thrombosis</b>	<i>Mountbatten Room</i>
	<i>Chairs: P Prandoni and MM Samama</i>	
	<ol style="list-style-type: none"><li>1. Prevention of cancer-associated thrombosis – Where are we today? <i>M Levine</i></li><li>2. Treatment of VTE in cancer patients <i>P Prandoni</i></li><li>3. Is there a biological rationale for anticoagulation in cancer therapy? <i>Lord Kakker</i></li></ol>	
<b>15.15 – 16.15</b>	<b>Plenary Session IV: Venous Thromboembolism</b>	
	<i>Chairs: H Büller, The Netherlands and S Goldhaber</i>	
	<ol style="list-style-type: none"><li>1. VTE treatment: The options in 2013 <i>S Haas</i></li><li>2. Secondary prevention: Who, how long, with what? <i>G Agnelli, Italy</i></li></ol>	
<b>16.15 – 17.00</b>	<b>Debate: Parenteral Anticoagulation Has No Future</b>	
	<i>Chair: Lord Kakkar</i>	
	<b>For:</b> <i>AGG Turpie</i>	
	<b>Against:</b> <i>H Büller</i>	
<b>17.00 – 17.15</b>	<b>Closing Remarks</b> <i>S Goldhaber</i>	





## Sylvia Haas

---

*Technical University of Munich, Munich, Germany*

Sylvia Haas, MD, PhD, is currently an emeritus professor of medicine and former director of the Haemostasis and Thrombosis Research Group at the Institute for Experimental Oncology and Therapy Research, Technical University of Munich, Germany.



Professor Haas' scientific focus is on the development of new antithrombotic therapies, laboratory monitoring of anticoagulants, biomarkers, and tumour-associated thrombosis. She is involved in several clinical trials, and in particular trials involving the prevention and treatment of arterial and venous thromboembolism.

Professor Haas is a member of several international professional societies, including the International Society on Thrombosis and Haemostasis and the International Society of Angiology. She is a fellow of the Southern African Society of Thrombosis and Haemostasis, the European Society for Surgical Research, and the German Societies of Surgery, Angiology, and Thrombosis and Haemostasis Research. Professor Haas is also a member of the editorial board for several peer-reviewed journals, including *Current Hematology Reports*, *International Journal of Angiology*, and *Clinical and Applied Thrombosis/Hemostasis*.

Professor Haas holds a medical degree from the University of Freiburg. She began her training in paediatric haematology and oncology at the University of Munich. She continued her training in internal medicine at the Medical School, Technical University of Munich, and she received full professorship after having established the Haemostasis and Thrombosis Research Group.

---



### **Lord Ajay K Kakkar**

---

*University College Hospital; Thrombosis Research Institute, London, United Kingdom*

Professor the Lord Kakkar, MBBS, BSc, PhD, FRCS, is professor of surgery, University College London; a consultant surgeon at the University College London Hospitals NHS Foundation Trust; chair for Clinical Quality, University College London Partners Academic Health Network; chair of the Health Honours Committee; commissioner of the Royal Hospital Chelsea; and member of the General Medical Council and director of the Thrombosis Research Institute, London, United Kingdom.

Lord Kakkar has been a fellow of the Royal College of Surgeons since 1992. He completed his medical degree at King's College Hospital Medical School and received his PhD from Imperial College London.

Lord Kakkar's research interests include the prevention and treatment of venous and arterial thromboembolic disease and cancer-associated thrombosis. His awards include Hunterian Professor, Royal College of Surgeons (1996), David Patey Prize, Surgical Research Society of Great Britain and Ireland (1996), Knoll William Harvey Prize, International Society on Thrombosis and Haemostasis (1997), James IV Association of Surgeons Travelling Fellow (2006), and Wellcome Memorial Lecture, Royal Society of Medicine (2009).

Lord Kakkar was created a life peer in 2010 and sits on the cross benches of the House of Lords.

---

## Vijay V Kakkar

---

*Thrombosis Research Institute, London, United Kingdom;  
Thrombosis Research Institute, Bangalore, India*



Vijay V Kakkar, OBE, FRCS, FRCSE, (Hon) DSc, is emeritus professor at the University of London and founder-president of the Thrombosis Research Institute, London, and founder-chair of the Thrombosis Research Institute, Bangalore.

Professor Kakkar graduated from Vikram University, Ujjain, India, in 1960, and qualified as fellow of the Royal College of Surgeons of Edinburgh and England in 1964.

Professor Kakkar has held a number of appointments at King's College, University of London, and has been the recipient of many distinctions and awards, including a Hunterian Professorship from the Royal College of Surgeons of England, visiting professor of Harvard University, honourable fellowship of the Association of Surgeons of India, a lifetime achievement award from the Union of Angiology, an honorary doctor of science from Loyola University of Chicago, and, in 2010, he was awarded an Order of the British Empire (OBE). He is a member of a number of professional societies and was a founding member of the British Society of Haemostasis and Thrombosis. His publications include more than 680 original articles, 6 books, and contributions to over 50 books.

In 1989, Professor Kakkar established the Thrombosis Research Institute as a national resource to provide a multidisciplinary environment dedicated to the study of thrombosis and related disorders.

---





### Mark Levine

---

*McMaster University, Hamilton, Ontario, Canada*

Mark Levine is chair and professor in the Department of Oncology at McMaster University, Hamilton, Ontario, Canada. He holds the Buffett Taylor chair in breast cancer research at McMaster University. He is a past recipient of the O Harold Warwick Prize (1999) from the National Cancer Institute of Canada.

Dr Levine received his medical degree from McGill University, Montreal, Quebec, Canada, and completed his residency in internal medicine at McMaster University. He completed his training in hematology and oncology at Duke University Medical Center, Durham, North Carolina, USA. In addition, Dr Levine received a master's degree in clinical epidemiology and biostatistics from McMaster University.

In 1982, Dr Levine became both a member of the Faculty of Health Sciences at McMaster University and a medical oncologist at the Hamilton Regional Cancer Centre (now known as the Juravinski Cancer Centre – Hamilton Health Sciences). He was the CEO of the cancer centre between 1992 and 1999. Over the past 29 years, he has been an active researcher in clinical trials and health services research. His focus is in the areas of breast cancer, thromboembolism in malignancy, and functional imaging. A number of the trials he has conducted have impacted health care in both Canada and internationally. He helped establish the Ontario Clinical Oncology Group (OCOG) in 1982 and is now the group's the director. OCOG is an academic group that designs, coordinates, and analyses multicentre trials in cancer. Dr Levine has more than 250 publications in peer-reviewed journals, and he has brought much research funding to McMaster University. He was chairman of Health Canada's Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Dr Levine was an associate editor of the *Journal of Clinical Oncology* for 7 years and is now a consultant editor.

---





## Giancarlo Agnelli

---

*University of Perugia, Perugia, Italy*

Giancarlo Agnelli, MD, is professor of internal medicine and director of the Division of Internal and Cardiovascular Medicine and Stroke-Unit at the University of Perugia, Perugia, Italy.



He received his degree in medicine and surgery from the University of Perugia in 1975, where he was subsequently appointed assistant professor at the Institute of Internal Medicine. He followed this with positions as research fellow in the Department of Medicine and clinical fellow of internal medicine at McMaster University, Hamilton, Ontario, Canada. In 1986, he was appointed research fellow at the Division of Thrombosis and Haemostasis, Department of Haematology, at the University of Amsterdam, Netherlands. In 1988, he was appointed associate member of the Hamilton Civic Hospital Research Centre, McMaster University, and in 1992, associate professor of internal medicine at the Institute of Internal and Vascular Medicine, University of Perugia.

Professor Agnelli is a member of the Conference on Antithrombotic Therapy of the American College of Chest Physicians, and the Italian Society for the Study of Haemostasis and Thrombosis.

Professor Agnelli has authored more than 300 publications in peer-reviewed international journals and is a member of the editorial boards for *Thrombosis Research*, *Haemostasis*, *Journal of Cardiovascular Medicine*, *Acta Cardiologica*, and *Trends in Medicine*. He also is a reviewer for *The New England Journal of Medicine*, *The Lancet*, *Circulation*, *Blood*, *Cardiovascular Research*, *Journal of Thrombosis and Haemostasis*, and the *Journal of the American College of Cardiology*.

---



### Dan Atar

---

*Oslo University Hospital, Ullevål University of Oslo, Oslo, Norway*

Dan Atar, MD, 54, is head of cardiology at Oslo University Hospital Ullevål, Oslo, Norway, and holds a full professorship in cardiology at the University of Oslo, Norway, along with a visiting associate professorship at the Johns Hopkins University, Baltimore, Maryland, USA.

Dr Atar trained in Denmark, Switzerland, and the United States before receiving his board certification in internal medicine and cardiology in 1995. His research focuses on myocardial biomarkers, myocardial function, heart failure, and cardiovascular pharmacology. He has written more than 200 articles and book chapters, and he holds FESC, FACC, and inaugural FAHA fellowship titles. Dr Atar is the past chair of the European Society of Cardiology (ESC) Working Group on Cardiovascular Pharmacology and Drug Therapy, and an associate editor of the international peer-reviewed journal *Cardiology* (Karger). He is currently chairing a European Union Seventh Framework Programme (EU-FP7) research consortium ('Mitocare'). He was on a number of ESC guideline-writing committees, amongst others, the '2010 ESC Guideline on Atrial Fibrillation' as well as the '2012 ESC Guideline Update on Atrial Fibrillation.' In 2012, Dr Atar was elected as councillor and board member of the ESC.

---

## Jean-Pierre Bassand

---

*University Hospital Jean-Minjoz, Besançon, France*

Jean-Pierre Bassand is professor of cardiology at the University of Besançon Franche-Comté in France, where he also completed his medical education. His research interests are in the diagnosis and treatment of venous thromboembolic disease and coronary artery disease, particularly acute coronary syndromes.

Professor Bassand was made a fellow of the European Society of Cardiology (ESC) and of the American College of Cardiology in 1990, and a fellow of the Royal College of Physicians (Glasgow) in 2007. He has served as a member of the board of the ESC for 10 years, including 2 years as the society's president. He has authored or co-authored over 200 manuscripts, including three ESC guidelines on the management of acute coronary syndromes and pulmonary embolism. He was awarded the American College of Cardiology Maseri-Florio Prize in 2009.

---





### Rupert Bauersachs

---

*Academic Medical Center, Amsterdam, The Netherlands*

Rupert Bauersachs, MD, is professor of internal medicine, director of the *Max-Ratschow Klinik* for Vascular Medicine at the Klinikum Darmstadt, Germany.

Professor Bauersachs received his medical degree from the University of Munich. He was a postdoctoral fellow at the Department of Pharmacology, University of Munich, Germany, and, subsequently, a research fellow of the American Heart Association at the Department of Physiology at the University of Southern California, USA. He completed his residency in internal medicine at the München-Bogenhausen Hospital and the Universities of Mainz and Frankfurt. Professor Bauersachs has been certified for internal medicine, vascular medicine, haemostaseology, diabetology, phlebology, and aviation medicine, and he is a fellow and national delegate of the International Union of Angiology.

In 1999, Professor Bauersachs became a faculty member of the University of Frankfurt and head of the department of vascular medicine. He was one of the founding members of the first German University Vascular Centers. In 2003, he was appointed director of the *Max-Ratschow Klinik* for Vascular Medicine. Professor Bauersachs is a council member for the German Societies for Angiology, Phlebology, and Microcirculation, and is active in various other societies for vascular medicine and thrombosis and hemostasis. His interests are venous thromboembolism, thrombophilia, antithrombotic agents, and women's issues in thrombosis. He has published more than 100 original papers, and his scientific work has been awarded several prizes.

His personal hobbies are music and sound engineering, mountain biking and sailing.

---



## Harry R Büller

---

*Academic Medical Center, Amsterdam, The Netherlands*

Harry R Büller, MD, is professor of internal medicine, specialising in vascular medicine, at the Academic Medical Center in Amsterdam, The Netherlands.



Professor Büller earned his MD and PhD at the University of Amsterdam. After graduating, he completed his research fellowship in haemostasis and thrombosis in the departments of medicine and clinical epidemiology and biostatistics at McMaster University in Hamilton, Ontario, Canada.

Professor Büller has authored and co-authored more than 500 scientific articles concerning topics in his field. He has been co-chair of the Amsterdam Institute for Cardiovascular Research and is chair of the Vascular Medicine Working Group. He is a reviewer for the *The New England Journal of Medicine*, *The Lancet*, *Archives of Internal Medicine*, and *European Journal of Clinical Investigation*, among others. He is a member of the editorial board of the *Annals of Internal Medicine*.

Professor Büller was chair of the 2004 CHEST conference on antithrombotic therapy for venous thromboembolic disease: the Seventh American College of Chest Physicians (ACCP) Conference on Antithrombotic and Thrombolytic Therapy. He is the recipient of the Established Investigator Award presented by the Dutch Heart Foundation, and he received the Dutch Society for Vascular Medicine Award in 2005. Since 2008, he has served as honorary professor of the Royal Netherlands Academy of Arts and Sciences.

---



### **John Camm**

---

*St George's University, London, United Kingdom*

Professor Camm is professor of clinical cardiology at St George's University, London and Imperial University, London, United Kingdom.

He is a leader in the field of electrocardiography and cardiac arrhythmias, and he sits on a number of society boards associated with the subjects, including the World Society of Arrhythmia (WSA) and the Atrial Fibrillation Task Force of the European Society of Cardiology (ESC), of which he is chair. He is also chair of the National Institute for Health and Clinical Excellence (NICE) Guidelines for Acute Coronary Syndromes and is a member of numerous cardiology societies.

Professor Camm is a major authority in the area of cardiology and has more than 1,200 peer-reviewed papers, 300 book chapters, and 35 books (as editor, author, or both) to his credit. He is also editor-in-chief of several leading cardiology journals, including *Europace* and *Clinical Cardiology*.

---

## Anna Falanga

*Ospedali Papa Giovanni XXIII, Bergamo, Italy*

Anna Falanga, MD, is head of the Division of Immuno-hematology/Transfusion Medicine and the Hemostasis and Thrombosis Center, at the Department of Oncology-Hematology of Ospedali Papa Giovanni XXIII, in Bergamo, Italy. She is also head of the Department of Transfusion Medicine and Hematology (DMTE) of the Province of Bergamo.



After having received her medical degree and board certification in internal medicine at the University of Naples, Italy, Dr Falanga obtained board certification in hematology at the University of Verona, Italy. Subsequently, she spent three years working as a postdoctoral fellow at the Mario Negri Institute in Milan, Italy, and a further two years at the University of Colorado School of Medicine, Denver, Colorado, USA. Her research focuses on cancer and thrombosis, specifically, the effect of malignant disease on the host hemostatic system, including the characterization of tumor cell procoagulant activities, and the pathogenesis and management of the thrombophilic state associated with malignancy. Her group is also involved in clinical trials to test the efficacy and safety of anticoagulant drugs to prevent thrombosis and improve survival in patients with cancer. She is on the panel of experts and a co-chair for the preparation of guidelines of prophylaxis and treatment of venous thromboembolism in patients with cancer, for the Italian Society of Medical Oncology, the American Society of Clinical Oncology, and the European Society of Medical Oncology.

Dr Falanga has authored more than 180 publications, including original articles, reviews, and book chapters. She has been guest editor of 15 books or journal supplements. She has been appointed professor of coagulation disorders at the School of Hematology, Faculty of Medicine, and of blood diseases at the postgraduate School of Obstetrics, University Bicocca, Milan, Italy. She has been chair of the Scientific and Standardization Committee of the International Society

of Thrombosis and Haemostasis (ISTH) (term 2010-2012), and a member (term 2007-2010) and chair (2011) of the Scientific Committee on Hemostasis of the American Society of Hematology (ASH). Further she is counsellor on the board of the European Hematology Association (EHA) (term 2009-2013) and the board of the Italian Federation of the Antithrombotic Centers (term 2009-2013). In July 2009, she was awarded the BACH Investigator Award of the ISTH. Dr Falanga has also organized numerous scientific conferences, including being co-chair of six editions of the International Conferences on 'Thrombosis and Hemostasis Issues in Cancer' (ICTHIC), in Bergamo, Italy.

---

## Keith AA Fox

---

*University of Edinburgh, Edinburgh, United Kingdom*

Keith Fox, MBChB, FRCP, FESC, FACC, FMedSci, is the British Heart Foundation and the Duke of Edinburgh Professor of Cardiology of the University of Edinburgh.



He was a founding fellow of the European Society of Cardiology (ESC) and is currently chair of the programme of the ESC. In addition, he was president of the British Cardiovascular Society from 2009 to 2012. Professor Fox gave the State-of-the-Art Lecture on acute coronary syndromes at the American Heart Association as well as the 2009 plenary lecture at the European Society of Cardiology – American College of Cardiology Symposium. He was awarded the Silver Medal of the ESC in 2010. In 2012, he presented the Lord Rayner Lecture of the Royal College of Physicians (London) and the Sir Stanley Davidson Lecture of the Royal College (Edinburgh).

Professor Fox's major research interest lies in the mechanisms and manifestations of acute coronary arterial disease. His work extends from underlying biological mechanisms to in vitro and in vivo studies and clinical trials. He is the author of more than 587 scientific papers (H index Web of Science 73, Citations: 30,261 to March 2013). His current areas of research include the inhibition of coronary thrombosis and the role of platelets and inflammation in acute coronary syndromes.

Professor Fox is chair of the RITA programme, co-chair of ROCKET-AF, and OASIS programme and chair of the GRACE programme (the largest multinational study in acute coronary syndromes), and a lead investigator for studies on novel antithrombins, anticoagulants, and antiplatelets. He is an international associate editor of the *European Heart Journal* and a member of the editorial boards of a number of journals.

---



### **Samuel Z Goldhaber**

---

*Harvard Medical School, Boston, Massachusetts, USA*

Samuel Z Goldhaber, MD, professor of medicine at Harvard Medical School, is a senior staff member of the Cardiovascular Medicine Division at Brigham and Women's Hospital (BWH). He is director of the BWH Thrombosis Research Group, medical co-director of the BWH Anticoagulation Management Service, and serves as Principal Investigator of a broad range of randomized clinical trials and observational studies related to the prevention, treatment, and epidemiology of venous thromboembolism, stroke prevention in atrial fibrillation, and prevention of recurrent myocardial infarction.

Dr Goldhaber serves on the Steering Committee of GARFIELD and is the national coordinator of participating USA sites in GARFIELD. He also serves as chair of the Steering Committee of the National Heart, Lung, and Blood Institute (NHLBI)-sponsored ATTRACT Trial of DVT thrombolysis and is a member of the Steering Committee of the NHLBI-sponsored COAG Trial of warfarin dosing with rapid turnaround genetic testing. For his work on prevention of venous thromboembolism, Dr Goldhaber has received a Certificate of Appreciation from the Surgeon General of the United States. Dr Goldhaber is president and founding director of the North American Thrombosis Forum ([www.NATFonline.org](http://www.NATFonline.org)). He serves as a section editor for *Circulation* and for *Thrombosis and Haemostasis*. He also has a busy practice of general cardiology, atrial fibrillation, and venous thromboembolism patients.

---

## Shinya Goto

---

*Tokai University School of Medicine; the Institute of Medical Science, Tokyo, Japan*



Shinya Goto, MD, PhD, is currently a professor in the Department of Medicine (Cardiology) at the Tokai University School of Medicine (Isehara), the director and chair of the Research Center of Metabolic Disease at Tokai University Graduate School of Medicine, and director of the Department of Metabolic System Medicine and the Institute of Medical Science of Tokai, all in Japan.

Professor Goto gained his qualification in medicine from the Keio University School of Medicine, Tokyo, Japan in 1986. After completion of his training course in clinical cardiology and cardiology-related biomedical research at the Keio University Graduate School of Medicine, he moved to the Department of Experimental Medicine, the Scripps Research Institute, La Jolla, California, USA, where he completed a postdoctoral fellowship.

Professor Goto's basic research achievements include dissecting the mechanism of platelet thrombus formation, especially under high-shear rate of flow conditions. Professor Goto also led many clinical studies both in Japan and worldwide, including 'Apixaban versus Warfarin in Patients with Atrial Fibrillation' and 'Rivaroxaban in Patients with a Recent Acute Coronary Syndrome.'

Professor Goto has published approximately 120 original peer-reviewed articles, which have appeared in highly respected journals such as *The New England Journal of Medicine*, the *Journal of Clinical Investigation*, *The Lancet*, *JAMA*, and *Circulation*. He is an editor of the *Journal of Atherosclerosis and Thrombosis*, *Thrombosis and Haemostasis*, *Archives of Medical Science*, and *International Review of Thrombosis*.

---





### **Werner Hacke**

---

*University Hospital of Heidelberg, Heidelberg, Germany*

Werner Hacke is professor and chairman of the Department of Neurology, University of Heidelberg, Germany. He graduated from the RWTH Aachen Medical School, and completed his training in neurology at the University of Aachen in Germany and the University of Berne in Switzerland.

Professor Hacke's main interests are cerebrovascular disorders and critical care neurology. He has published more than 300 articles and is the sole author of *Neurologie*, the leading German textbook of neurology. He has received a number of prestigious awards and is an honorary member of the American Neurological Association, the French Neurological Society, and the Panrussian Federation of Neurology. He was the president of the German Neurological Society, the German Stroke Society, the German Critical Care Medicine society, and the founding president of the European Stroke Organisation. He was chair of the Scientific Committee of the World Stroke Conference (2008, 2010, and 2012) as well as chair of the World Congress of Neurology scientific board in 2011 and 2013. He is currently the first vice president of the World Federation of Neurology.

---

## Craig M Kessler

---

*Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center, Washington, DC, USA*



Craig M Kessler, MD, received his medical degree from the Tulane University School of Medicine in New Orleans, Louisiana, where he was a member of Alpha Omega Alpha Honor Society. He completed his residency in internal medicine at the Ochsner Foundation Hospital in Louisiana and his fellowship in hematology/oncology at the Johns Hopkins Hospital and University in Baltimore, Maryland.

Dr Kessler then became a full-time faculty member and attending physician in the Section of Special Hematology at the National Institutes of Health in Bethesda, Maryland. In 1982, he joined the Division of Hematology and Oncology at the George Washington University School of Medicine, where he became tenured professor of medicine and chief of the division. He is currently professor of medicine and pathology at the Georgetown University Medical Center and the Lombardi Comprehensive Cancer Center. In addition, Dr Kessler is director of the Division of Coagulation, director of cellular and therapeutic apheresis, director of the Hemophilia and Thrombophilia Comprehensive Treatment Center, and immediate past chief of the Division of Hematology/Oncology.

He is co-editor of Haemophilia and Seminars in Thrombosis and Hemostasis, and is chair of the Medical and Scientific Advisory Council of the National Hemophilia Foundation. Dr Kessler has been awarded Mastership in the American College of Physicians and has published 4 books and more than 175 peer-reviewed articles.

---



### **Jessica Mega**

---

*Brigham and Women's Hospital, Boston, Massachusetts, USA*

Jessica Mega, MD, MPH, is a cardiologist at Brigham and Women's Hospital, where she attends in the Cardiac Intensive Care Unit, and is a faculty member at Harvard Medical School, Boston, Massachusetts, USA. She is an investigator with the TIMI Study Group and director of TIMI's Genetics Core Laboratory. She is board certified in internal medicine and cardiology, and is a fellow of the American Heart Association and the American College of Cardiology.

Dr Mega has been involved in the leadership of clinical trials evaluating novel antithrombotic therapies, including ATLAS ACS -TIMI 46 and ATLAS ACS 2-TIMI 51. Her research also focuses on the use of biomarkers and genetics to stratify risk and evaluate therapies in cardiovascular patients. She was principal investigator for the ELEVATE-TIMI 56 trial, which evaluated escalating doses of clopidogrel based on CYP2C19 genotype in cardiac patients. She has also studied genetic variants that relate to other cardiovascular therapies including anticoagulants and lipid-lowering medications. Her work has been published in high-impact medical journals including *The New England Journal of Medicine*, *The Lancet*, and *JAMA*, and she has been awarded research grants from the American Heart Association and the National Institutes of Health.

---

## Paolo Prandoni

---

*University of Padova, Padova, Italy*

Paolo Prandoni, PhD, is professor at the Department of Cardiothoracic and Vascular Sciences, Thromboembolism Unit at the University of Padova in Italy. He trained at the University of Padova from 1971 to 1979 before moving to Holland where he studied for his PhD at the University of Amsterdam in 1992. Professor Prandoni's research and professional experiences cover epidemiology, diagnosis, and management of thromboembolism. Of particular interest are studies addressing the association of cancer with venous thromboembolism.



Professor Prandoni has published more than 300 papers in peer-reviewed journals. His key achievements include the demonstration of the value of real-time compression ultrasonography for the diagnosis of DVT; the confirmation of the risk for subsequent overt cancer in patients with idiopathic VTE; the demonstration that LMWHs are as effective and safe as UFH in the treatment of DVT; the demonstration that LMWHs allow the home treatment of DVT; the description of the natural history of DVT, outlining the particularly high risk of recurrent thromboembolism in cancer patients; the demonstration that both factor V Leiden and G20210A prothrombin variant are independent risk factors for recurrent VTE; the demonstration that residual vein thrombosis is a predictive marker of recurrent thromboembolism; the demonstration that cancer patients with venous thrombosis have a high risk of recurrent thromboembolism while on anticoagulation; the demonstration of an association between atherosclerosis and venous thrombosis; and the demonstration that chronic pulmonary thromboembolic hypertension after an episode of pulmonary embolism is more frequent than commonly thought.

---



### Meyer-Michel Samama

---

*Hôtel-Dieu University Hospital, Paris, France*

Meyer-Michel Samama, MD, PharmD, is professor emeritus of haematology at Hôtel-Dieu University Hospital, Faculty of Medicine, Paris, France, where he was formerly chairman of the Department of Haematology and scientific adviser and delegate director at Biomnis Laboratory. He qualified as a pharmacist-pathologist then as a medical doctor and then as professor of haematology from the Paris VI University School of Medicine. His study on venous thromboembolism prophylaxis in medical patients (Medenox study) was selected to be presented at the Presidential Symposium of the International Society on Thrombosis and Haemostasis in 1999 and is a frequently quoted work published in *The New England Journal of Medicine*.

Dr Samama's research interests center on haemostasis and pathogenesis of venous thrombosis. Current fields of focus include the diagnosis and treatment of hereditary thrombophilia and the pharmacology of antithrombotic drugs including low-molecular-weight heparins, fondaparinux, and new antithrombotic agents. He has published more than 400 original articles and has co-edited a number of books on clinical thrombosis and hypercoagulable states. He received a Distinguished Career Award for his contributions to haemostasis from the International Society on Thrombosis and Haemostasis. He also received an award from the International Society of Fibrinolysis and Thrombolysis and from the Venous Thrombosis forum for his contribution to the field.

Dr Samama is a member of the editorial board of the *Journal of Thrombosis and Haemostasis*, sits on the review board of several journals, and is a member of several professional societies. He is a member of the American College of Chest Physicians (ACCP) Consensus Conference on antithrombotic therapy. He was elected corresponding member of the National Academy of Pharmacy in 2001. In addition, Dr Samama has presented several lectures at the National Academy of Medicine.

---

## Alexander G G Turpie

---

*McMaster University and Hamilton Health Sciences,  
Hamilton, Ontario, Canada*



Alexander Turpie, MD, is professor of medicine at McMaster University and an internist on the staff of Hamilton Health Sciences. He received his medical education from the University of Glasgow, Scotland. After completing residencies at the Glasgow Royal Infirmary and Stobhill General Hospital, where he was also a clinical research fellow, he served as a clinic lecturer for the University of East Africa Medical School in Nairobi, Kenya. After returning to the University of Glasgow for additional training in hemostasis and thrombosis, he was appointed MRC Fellow at McMaster University as well as being appointed to the full-time faculty in the Department of Medicine.

Professor Turpie's research interests include new antithrombotic drugs for the management of venous and arterial thrombosis, and anticoagulant therapy in patients with prosthetic heart valves. He has served on numerous professional and university-related committees and is a frequent lecturer at professional meetings worldwide.

Professor Turpie has authored more than 700 published articles, abstracts, book chapters, and books, and he has been a reviewer for many journals, including the *Annals of Internal Medicine*, *Circulation*, *The Lancet*, and *The New England Journal of Medicine*. In addition, he serves on the editorial boards of *Vascular Medicine* and *Heart Drug*.

---

























































Organized under the auspices of the Thrombosis Research Institute, London, United Kingdom  
and supported by Bayer Healthcare Pharmaceuticals, Boehringer Ingelheim, Daiichi Sankyo, Pfizer and Sanofi.